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Introduction: ST-elevation myocardial infarction (STEMI) is responsible for high morbidity and mortality, and new classes of drugs are being added 
to its treatment overtime. The real benefit versus the bleeding risk of the associations is not yet known, given the large diversity of regimens and 
doses. Objectives: Assess, by systematic review, the impact of the progressive addition of thrombolytics, anticoagulants, antiplatelets and primary PCI 
on 30-day outcomes: death, reinfarction (AMI) and major bleeding (MB) in patients with STEMI. 
Methods: A Medline search with the words “acute”, “myocardial infarction / therapy” was performed, to identify randomized trials comparing these 
classes of drugs in adults with STEMI, at least 500 patients. The study should provide death, AMI and MB rates. Similar arms were grouped, and the 
correlation between progressive addition of drugs, number of drugs and primary PCI and the outcomes were evaluated by Spearman coefficient and 
multivariate regression, as well as the correlation between the year and era of the study and the outcomes. 
Results: The search resulted in 2313 articles; 59 remained after exclusions. 404.556 patients, with mean follow up time of 23.3 days, were divided 
into 35 groups of treatment arms. There was a trend towards the correlation between gradual introduction of drugs (12 groups) and death (r = 
-0.564, p = 0.056) and MB (r = 0.571, p = 0.053). There was significant correlation between the number of drugs and the rates of death (r = -0.466, 
p = 0.005) and MB (r = 0.403, p = 0.016), confirmed by multivariate regression model. This model also showed that primary PCI had additional 
benefit over mortality compared to the number of drugs, as well as increased MB risk. The year of the study had significant correlation with the 3 
outcomes assessed: death (r = -0.380, <0.001), MB (r = 0.212, p = 0.014) and AMI (r = -0.231, p = 0.009), as well as the era of accomplishment. 
Conclusion: The increasing complexity of STEMI treatment resulted in significant reduction in mortality and increased rates of MB, that does not 
nullify the net clinical benefit. There is correlation between the year and the age of the study and reduction of mortality and AMI, with a concomitant 
increase in MB.
